NCT02728830View on ClinicalTrials.gov

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2022

Conditions
Gynecologic NeoplasmsEpithelial Ovarian CancerUterine Endometrial CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg IV

Trial Locations (1)

27710

Duke Cancer Institute, Durham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AA Secord

OTHER

NCT02728830 - A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Biotech Hunter | Biotech Hunter